Human papillomavirus infections among Japanese women: Age-related prevalence and type-specific risk for cervical cancer

Cancer Science

Volumn 100, Issue 7, 2009, Pages 1312-1316

  Onuki, Mamiko ^a   Matsumoto, Koji ^a   Satoh, Toyomi ^a   Oki, Akinori ^a   Okada, Satoshi ^a   Minaguchi, Takeo ^a   Ochi, Hiroyuki ^a   Nakao, Sari ^a   Someya, Katsumi ^b   Yamada, Naoki ^c   Hamada, Hiromi ^a   Yoshikawa, Hiroyuki ^a  

^a UNIVERSITY OF TSUKUBA   (Japan)

^b Ibaraki Seinan Medical Center Hospital   (Japan)

^c Mito Saiseikai General Hospital   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

VIRUS DNA; WART VIRUS VACCINE;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; ARTICLE; CANCER GRADING; CANCER GROWTH; CANCER RISK; CANCER SCREENING; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HUMAN CELL; HUMAN PAPILLOMAVIRUS INFECTION; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; HUMAN PAPILLOMAVIRUS TYPE 31; HUMAN PAPILLOMAVIRUS TYPE 33; HUMAN PAPILLOMAVIRUS TYPE 35; HUMAN PAPILLOMAVIRUS TYPE 52; HUMAN PAPILLOMAVIRUS TYPE 58; JAPANESE; MAJOR CLINICAL STUDY; MIXED INFECTION; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX CARCINOMA IN SITU; UTERINE CERVIX CYTOLOGY; VIRAL PHENOMENA AND FUNCTIONS; VIRAL PREVALENCE; VIRUS EXAMINATION; VIRUS INFECTION; WOMEN'S HEALTH;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ASIAN CONTINENTAL ANCESTRY GROUP; EARLY DETECTION OF CANCER; FEMALE; HUMANS; JAPAN; MIDDLE AGED; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; PREVALENCE; RISK FACTORS; UTERINE CERVICAL NEOPLASMS;

EID: 67449087430     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01161.x     Document Type: Article

References (26)

1. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007; 370: 890-907.
2. Wright TC Jr, Schiffman M, Solomon D et al. Interim guidance for the use of human papillomavirus DNA testing as an adjunct to cervical cytology for screening. Obstet Gynecol 2004; 103: 304-9.
3. Future II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 1915-27.
4. Harper DM, Franco EL, Wheeler CM et al. Sustained efficacy up to 4.5.years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: Follow-up from a randomised control trial. Lancet 2006; 367: 1247-55.
5. Paavonen J, Jenkins D, Bosch FX et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: An interim analysis of a phase III double-blind, randomised controlled trial. Lancet 2007; 369: 2161-70.
6. Mayrand MH, Duarte-Franco E, Rodrigues I et al. Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med 2007; 357: 1579-88.
7. Naucler P, Ryd W, Törnberg S et al. Human papillomavirus and Papanicolaou tests to screen for cervical cancer. N Engl J Med 2007; 357: 1589-97.
8. Miura S, Matsumoto K, Oki A et al. Do we need a different strategy for HPV screening and vaccination in East Asia? Int J Cancer 2006; 119: 2713-15.
9. Yoshikawa H, Kawana T, Kitagawa K, Mizuno M, Yoshikura H, Iwamoto A. Detection and typing of multiple genital human papillomaviruses by DNA amplification with consensus primers. Jpn J Cancer Res 1991; 82: 524-31.
10. Kado S, Kawamata Y, Shino Y et al. Detection of human papillomaviruses in cervical neoplasias using multiple sets of generic polymerase chain reaction primers. Gynecol Oncol 2001; 81: 47-52.
11. Harnish DG, Belland LM, Scheid EE, Rohan TE. Evaluation of human papillomavirus-consensus primers for HPV detection by the polymerase chain reaction. Mol Cell Probes 1999; 13: 9-21.
12. Statistical Survey Department. Japan population census 2005 (Website on the internet). Tokyo: Statistics Bureau, Ministry of Internal Affairs and Communications, 2005. [Cited 5 March 2009]Available from URL: http://www.stat.go.jp/english/data/kokusei/index.htm.
13. Matsuda T, Marugame T, Kamo KI et al. Cancer incidence and incidence rates in Japan in 2002: Based on data from 11 population-based cancer registries. Jpn J Clin Oncol 2008; 38: 641-8.
14. Yoshikawa H, Nagata C, Noda K et al. Human papillomavirus infection and other risk factors for cervical intraepithelial neoplasia in Japan. Br J Cancer 1999; 80: 621-4.
15. Sasagawa T, Basha W, Yamazaki H, Inoue M. High-risk and multiple human papillomavirus infections associated with cervical abnormalities in Japanese women. Cancer Epidemiol Biomarkers Prev 2001; 10: 45-52.
16. Asato T, Maehama T, Nagai Y, Kanazawa K, Uezato H, Kariya K. A large case-control study of cervical cancer risk associated with human papillomavirus infection in Japan, by nucleotide sequencing-based genotyping. J Infect Dis 2004; 189: 1829-32.
17. Dunne EF, Unger ER, Sternberg M et al. Prevalence of HPV infection among females in the United States. JAMA 2007; 297: 813-19.
18. Kjaer SK, Breugelmans G, Munk C, Junge J, Watson M, Iftner T. Population-based prevalence, type- and age-specific distribution of HPV in women before introduction of an HPV-vaccination program in Denmark. Int J Cancer 2008; 123: 1864-70.
19. Herrero R, Castle PE, Schiffman M et al. Epidemiologic profile of type-specific human papillomavirus infection and cervical neoplasia in Guanacaste, Costa Rica. J Infect Dis 2005; 191: 1796-807.
20. de SanjoséS, Diaz M, Castellsagué X et al. Worldwide prevalence and genotype distribution of cervical human papillomavirus DNA in women with normal cytology: A meta-analysis. Lancet Infect Dis 2007; 7: 453-9.
21. Muñoz N, Bosch FX, Castellsagué X et al. Against which human papillomavirus types shall we vaccinate and screen? The international perspective. Int J Cancer 2004; 111: 278-85.
22. Nakagawa S, Yoshikawa H, Onda T, Kawana T, Iwamoto A, Taketani Y. Type of human papillomavirus is related to clinical features of cervical carcinoma. Cancer 1996; 78: 1935-41.
23. Konno R, Shin HR, Kim YT et al. Human papillomavirus infection and cervical cancer prevention in Japan and Korea. Vaccine 2008; 26 (Suppl. 12): M30-42.
24. Khan MJ, Castle PE, Lorincz AT et al. The elevated 10-year risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst 2005; 97: 1072-9.
25. Vinokurova S, Wentzensen N, Kraus I et al. Type-dependent integration frequency of human papillomavirus genomes in cervical lesions. Cancer Res 2008; 68: 307-13.
26. Kyrgiou M, Koliopoulos G, Martin-Hirsch P, Arbyn M, Prendiville W, Paraskevaidis E. Obstetric outcomes after conservative treatment for intraepithelial or early invasive cervical lesions: Systematic review and meta-analysis. Lancet 2006; 367: 489-98.